Cargando…

Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland

INTRODUCTION: The role of the BRCA1 and BRCA2 genes in bladder and renal tumorigenesis is unclear. Our goal was to determine the prevalence of specific founder mutations genes BRCA1 (5328 insC, C61G and 4153 delA) and BRCA2 (C5972T) mutations in bladder and kidney cancer patients from Poland. MATERI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Złowocka-Perłowska, Elżbieta, Tołoczko-Grabarek, Aleksandra, Narod, Steven A., Lubiński, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994347/ https://www.ncbi.nlm.nih.gov/pubmed/35395863 http://dx.doi.org/10.1186/s13053-022-00220-6

Ejemplares similares

Germline HOXB13 mutation p.G84E do not confer an increased bladder or kidney cancer risk in polish population
por: Złowocka-Perłowska, Elżbieta, et al.
Publicado: (2022)

Bladder cancer survival in patients with NOD2 or CDKN2A variants
por: Złowocka-Perłowska, Elżbieta, et al.
Publicado: (2022)

Survival of bladder or renal cancer in patients with CHEK2 mutations
por: Złowocka-Perłowska, Elżbieta, et al.
Publicado: (2021)

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
por: Kluz, Tomasz, et al.
Publicado: (2018)

Serum concentration of iron as predictor of cancer risk among BRCA1 mutation carriers
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

Recurrent PALB2 mutations and the risk of cancers of bladder or kidney in Polish population
por: Złowocka-Perłowska, Elżbieta, et al.
Publicado: (2021)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Serum concentration of selected macro- and microelements and their correlation with the risk of breast and ovarian cancer among BRCA1 mutation carriers
por: Muszyńska, Magdalena, et al.
Publicado: (2012)

Selenium and risk of bladder cancer
por: Złowocka-Perłowska, E, et al.
Publicado: (2012)

Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland
por: Jasiewicz, Andrzej, et al.
Publicado: (2022)

Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
por: Wojcik, P., et al.
Publicado: (2016)

Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2005)

Looking for BRCA1 and BRCA2 mutations in Asian women with breast cancer
por: Narod, Steven A.
Publicado: (2023)

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2012)

Breast cancer prevention in women with a BRCA1 or BRCA2 mutation
por: Metcalfe, Kelly A, et al.
Publicado: (2007)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study
por: Iqbal, Javaid, et al.
Publicado: (2016)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet
por: Huzarski, Tomasz, et al.
Publicado: (2006)

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Odén, Lovisa, et al.
Publicado: (2016)

Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Zaman, Tasnim, et al.
Publicado: (2019)

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation
por: Metcalfe, Kelly, et al.
Publicado: (2019)

A common missense variant in BRCA2 predisposes to early onset breast cancer
por: Górski, Bohdan, et al.
Publicado: (2005)

BRCA1 and BRCA2 germline mutation analysis in the Indonesian population
por: Purnomosari, Dewajani, et al.
Publicado: (2007)

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations
por: Wang-Gohrke, S, et al.
Publicado: (1999)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Response to ‘Comments on 'The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study''
por: Narod, Steven A
Publicado: (2016)

Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study
por: de Jonge, Marthe M, et al.
Publicado: (2021)

Identification of patients at high risk of negative psychological consequences associated with BRCA1 mutation
por: Ertmański, S, et al.
Publicado: (2012)

Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2018)

Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012)

Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer
por: Henouda, Sarra, et al.
Publicado: (2016)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
por: Vos, Shoko, et al.
Publicado: (2017)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers
por: Eisen, Andrea, et al.
Publicado: (2008)

Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer?
por: Nguyen-Dumont, Tu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cofnppgf7sthiah9o4obtn87uc